ANORO IMPROVED HEALTH-RELATED QUALITY OF LIFE VS PLACEBO, AS MEASURED BY THE SGRQ8,9

The St. George’s Respiratory Questionnaire (SGRQ) is a respiratory disease-specific, patient-reported instrument containing 76 items that measures10:

 

Studied in patients with moderate or worse COPD (GOLD 2-4).8,9

Quality of Life Data_Icon_1@2x

Activities

Quality of Life Data_Icon_2@3x

Symptoms

Quality of Life Data_Icon_3@2x

Impact on daily life

QFL main image

What could an improvement in health-related quality of life mean for your patients with COPD?

ANORO demonstrated an improvement in health-related quality of life vs placebo as measured by a decrease from baseline in mean SGRQ total score of:

  • -5.51 unit difference (-8.07 vs -2.56)8
  • -4.03 unit difference (-6.15 vs -2.12)9§

*Defined as a decrease of at least 4 units from baseline.

Compared with placebo on Day 168; not adjusted for multiplicity.

Compared with placebo on Day 84; not adjusted for multiplicity.

§Compared with placebo on Day 84 (< 0.001).

  • DESCRIPTION OF STUDIES

    Study DB21133738

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluated the efficacy and safety of ANORO ELLIPTA (n=413), placebo (n=280), and other treatment arms, each administered once daily, in patients with COPD. For the primary endpoint, ANORO improved trough FEV1 by 167 mL (P<0.001) vs placebo at Day 169. Health outcomes assessments in this study included SGRQ total score and proportion of responders to SGRQ at Week 24.

    Study 2012119

    A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluated the efficacy and safety of ANORO ELLIPTA (n=248) compared with placebo (n=248) in patients with COPD. The primary endpoint was the SGRQ total score at Week 12. Proportion of responders to SGRQ at Week 12 was another endpoint.